352 material Form 8-K filings that 310 companies we cover made with the SEC in August 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Cabot reported third-quarter fiscal 2024 results on August 5, 2024, with adjusted EPS of $1.92, up 35% from $1.42, and net sales of $1,016 million, up from $968 million. The company raised its fiscal 2024 adjusted EPS guidance to $7.00 to $7.10 from $6.65 to $6.85, which points to higher expected profit for the full year.
Diluted EPS of $1.94 versus $1.43 a year earlier; adjusted EPS of $1.92 versus $1.42
Net sales and other operating revenues of $1,016 million versus $968 million in the same quarter last year
Fiscal 2024 adjusted EPS guidance raised to $7.00 to $7.10 from $6.65 to $6.85
Returned $73 million to shareholders in the quarter, including $24 million in dividends and $49 million in share repurchases
J&J Snack Foods reported fiscal third-quarter 2024 net sales of $440.0 million, up 3.3%, and net earnings of $36.3 million, up 3.8%, with diluted EPS of $1.87 versus $1.81 a year earlier. Growth came mainly from the Retail and Food Service segments, while Frozen Beverages sales declined 2.6% due to weaker movie theater attendance, which matters to shareholders as it shows continued top-line and profit growth despite a segment-level drag.
Net sales rose 3.3% to $440.0 million; net earnings rose 3.8% to $36.3 million.
Diluted EPS was $1.87 versus $1.81 a year earlier; adjusted EPS was $1.98 versus $1.92.
Retail segment sales rose 12.4% to $68.7 million; Frozen Beverages sales fell 2.6% to $106.8 million.
Management said fiscal fourth quarter results will be impacted by one less sales week than the prior-year period; the filing gives no numeric outlook.
Addus HomeCare reported second-quarter 2024 net service revenues of $286.9 million, up 10.4% from a year earlier, with net income of $18.1 million, or $1.10 per diluted share, compared with $14.9 million, or $0.91, in the prior-year quarter. Results also covered a pending $350.0 million acquisition of Gentiva's personal care operations, a planned sale of its New York operations, and a public offering that raised net proceeds of about $176.1 million.
Net service revenues rose 10.4% to $286.9 million; adjusted EBITDA rose 24.7% to $35.3 million.
Net income was $18.1 million, or $1.10 per diluted share, versus $0.91 a year earlier; adjusted EPS was $1.35 versus $1.07.
Cash was $173.3 million at June 30, 2024; about $81.4 million of offering proceeds repaid all credit facility debt.
The Gentiva acquisition is expected to close in the fourth quarter of 2024, subject to regulatory approvals.
Fidelity National Financial reported second quarter 2024 results on August 5, 2024, with GAAP net earnings attributable to common shareholders of $306 million, or $1.12 per diluted share, up from $219 million, or $0.81, a year earlier. Adjusted net earnings rose to $338 million, or $1.24 per share, from $274 million, or $1.01, and total revenue was $3,158 million versus $3,068 million, so the headline measures improved for shareholders. The filing contains no updated financial guidance.
Total revenue of $3,158 million for the quarter, compared with $3,068 million in the second quarter of 2023
Adjusted pre-tax title margin of 16.2%, compared with 15.8% a year earlier
F&G Segment adjusted net earnings of $122 million, compared with $67 million; F&G record gross sales of $4.4 billion, up 47%
Common dividend of $0.48 per share, totaling $131 million, paid in the quarter
AECOM reported third quarter fiscal 2024 results for the quarter ended June 30, 2024, with revenue up 13% to $4.2 billion and net income attributable to AECOM from continuing operations of $129 million, compared with a loss a year earlier. The company raised its fiscal 2024 earnings guidance, including adjusted EPS of $4.45 to $4.55, and said it has returned $407 million to shareholders so far this fiscal year.
Q3 revenue rose 13% to $4.2 billion; operating income was $227 million versus a loss of $105 million a year earlier.
Diluted EPS from continuing operations was $0.95, versus a loss of $0.90 in the prior-year quarter; adjusted EPS rose 23%.
Fiscal 2024 guidance raised to adjusted EBITDA of $1,075 million to $1,105 million and adjusted EPS of $4.45 to $4.55.
Company repurchased $150 million of stock since the quarter ended and has more than $700 million remaining under its repurchase authorization.
Palomar Holdings reported second quarter 2024 net income of $25.7 million, or $1.00 per diluted share, up from $17.6 million, or $0.69, a year earlier, with gross written premiums up 40.4% to $385.2 million. The company raised its full-year 2024 adjusted net income guidance to $124 million to $130 million, which includes catastrophe losses from Hurricanes Beryl and Debby. For shareholders, the filing shows higher profit and a higher outlook for the year.
Q2 2024 net income was $25.7 million, or $1.00 per diluted share, versus $17.6 million, or $0.69, in Q2 2023.
Adjusted net income was $32.0 million, or $1.25 per diluted share, versus $21.8 million, or $0.86, in Q2 2023.
Full-year 2024 adjusted net income guidance is now $124 million to $130 million.
Gross written premiums rose 40.4% to $385.2 million; the combined ratio was 79.1%, compared with 79.0% a year earlier.
Krystal Biotech reported second-quarter 2024 product revenue of $70.3 million from VYJUVEK, up 55.3% from the first quarter, and net income of $15.6 million ($0.53 per diluted share), compared with a net loss of $33.2 million a year earlier. Results include a $12.5 million litigation settlement charge, and the company kept its 2024 R&D and SG&A expense guidance of $150 million to $175 million (non-GAAP, excluding stock-based compensation) unchanged.
Q2 2024 product revenue, net: $70.3 million, up 55.3% from Q1 2024; gross margin 91%
Q2 2024 net income: $15.6 million, or $0.53 per diluted share, versus a net loss of $33.2 million in Q2 2023
Q2 2024 included a $12.5 million litigation settlement expense
Cash, cash equivalents and investments: $628.9 million as of June 30, 2024; 2024 R&D and SG&A guidance unchanged
Carlyle reported second-quarter 2024 results that show a sharp year-over-year improvement. Net income attributable to common stockholders was $148 million, or $0.40 per diluted share, compared with a loss of $98 million in the second quarter of 2023. The company also declared a quarterly dividend of $0.35 per share, payable August 26, 2024, to holders of record on August 16, 2024.
Total revenues were $1,069.7 million in Q2 2024, up from $462.1 million in Q2 2023.
Fee Related Earnings were $273 million, up 32% from $207 million, with an FRE margin of 46%.
Distributable Earnings were $343 million, or $0.78 per common share after tax, versus $389 million in Q2 2023.
Carlyle repurchased or withheld 4.1 million shares for $178 million in Q2 2024, leaving $1.1 billion of repurchase capacity.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.